Davide Ravizza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Davide Ravizza has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Cristina Trovato
Division of Endoscopy, European Institute of Oncology, Milan, Italy
7 shared publications Darina Tamayo
7 shared publicationsGiuseppe De Roberto
7 shared publicationsGiancarla Fiori
European Institute of Oncology (IEO), IRCCS
6 shared publicationsCristiano Crosta
5 shared publications- Nicola Fazio
Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IRCCS, Milan, Italy
4 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (7)
Breaking the Size Barrier: Endoscopic Submucosal Dissection of a Massive Flat Gastric Neuroendocrine Tumor
Type I gastric neuroendocrine tumors, arising in chronic atrophic gastritis, are usually small, mucosal, or submucosal elevated lesions. Current guidelines recommend endoscopic resection of lesions ≤20 mm and surgical treatment for those >20 mm. We report an unusual case of a 56-year-old woman with a completely flat (Paris 0-IIb) gastric body neuroendocrine tumor (NET) measuring 140 × 35 mm, detected by virtual chromoendoscopy and successfully resected by endoscopic submucosal dissection without complications. Histology revealed about 40 well-differentiated low-grade NET foci. After 6 months, no recurrence occurred, confirming endoscopic submucosal dissections curative potential in this exceptional giant but flat NET case.
- 1 July 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (7)
Open AccessBreaking the Size Barrier: Endoscopic Submucosal Dissection of a Massive Flat Gastric Neuroendocrine Tumor
Type I gastric neuroendocrine tumors, arising in chronic atrophic gastritis, are usually small, mucosal, or submucosal elevated lesions. Current guidelines recommend endoscopic resection of lesions ≤20 mm and surgical treatment for those >20 mm. We report an unusual case of a 56-year-old woman with a completely flat (Paris 0-IIb) gastric body neuroendocrine tumor (NET) measuring 140 × 35 mm, detected by virtual chromoendoscopy and successfully resected by endoscopic submucosal dissection without complications. Histology revealed about 40 well-differentiated low-grade NET foci. After 6 months, no recurrence occurred, confirming endoscopic submucosal dissections curative potential in this exceptional giant but flat NET case.
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S191
Feasibility, safety and efficacy of partially covered self-expandable metal stents for leaks after esophageal or gastric resection for malignances: a single center experience
Aims to assess the feasibility, safety and efficacy of partially covered self-expandable metal stents (PC SEMS) for leaks after esophageal or gastric resection for malignances Methods we retrospectively collected data of patients from November 2018 to October 2022 Results 23 patients (18 M, median age 70 yrs) were included. 11 patients had an esophagogastric anastomosis, 11 an esophagojejunal anastomosis and 1 an esophago-colonic anastomosis. 22 defects were anastomotic leak, 1 was a leak of the jejunal cul-de-sac. The median time between surgery and leak diagnosis was 8 (3-44) days. 20 (87 %) patients received Boston Ultraflex partially covered stent (100/120/150 mmx18/23 mm) and 3 (13 %) patients Boston Agile partially covered stent (120/150x23 mm). Stent placement was technically successful in all patients. The median time between stent placement and removal was 29 (4-52) days. One patient died for other causes with stent in place. PC SEMS retrieval was safe and easy, except for one patient who needed stent-in-stent technique for the subsequent successful removal. 15/22 and 2/22 patients obtained leak resolution after one and two stent placement respectively, with an overall success rate of 77%. Concerning patients with persistent leak, 1 patient achieved defect healing with Esosponge, 4 (17%) patients needed reintervention. During a median follow-up time of 4.4 (1.1-35.2) months, complications were observed in 4/22 (18%) patients: 2 migrations, 1 stricture at the level of the proximal stent margin, 1 self-limiting haemorrage Conclusions PC SEMS placement is a feasible, safe and effective technique for leak treatment after esophageal or gastric surgery for malignances Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 14 April 2023
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 55 (S 02) , S191
Feasibility, safety and efficacy of partially covered self-expandable metal stents for leaks after esophageal or gastric resection for malignances: a single center experience
Aims to assess the feasibility, safety and efficacy of partially covered self-expandable metal stents (PC SEMS) for leaks after esophageal or gastric resection for malignances Methods we retrospectively collected data of patients from November 2018 to October 2022 Results 23 patients (18 M, median age 70 yrs) were included. 11 patients had an esophagogastric anastomosis, 11 an esophagojejunal anastomosis and 1 an esophago-colonic anastomosis. 22 defects were anastomotic leak, 1 was a leak of the jejunal cul-de-sac. The median time between surgery and leak diagnosis was 8 (3-44) days. 20 (87 %) patients received Boston Ultraflex partially covered stent (100/120/150 mmx18/23 mm) and 3 (13 %) patients Boston Agile partially covered stent (120/150x23 mm). Stent placement was technically successful in all patients. The median time between stent placement and removal was 29 (4-52) days. One patient died for other causes with stent in place. PC SEMS retrieval was safe and easy, except for one patient who needed stent-in-stent technique for the subsequent successful removal. 15/22 and 2/22 patients obtained leak resolution after one and two stent placement respectively, with an overall success rate of 77%. Concerning patients with persistent leak, 1 patient achieved defect healing with Esosponge, 4 (17%) patients needed reintervention. During a median follow-up time of 4.4 (1.1-35.2) months, complications were observed in 4/22 (18%) patients: 2 migrations, 1 stricture at the level of the proximal stent margin, 1 self-limiting haemorrage Conclusions PC SEMS placement is a feasible, safe and effective technique for leak treatment after esophageal or gastric surgery for malignances Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
Nodal Merkel Cell Carcinoma with Unknown Primary Site and No Distant Metastasis: A Single-Center Series
Merkel cell carcinoma (MCC) is a very rare and aggressive neuroendocrine carcinoma originating from Merkel cells, typically with a skin nodule; however, it exceptionally presents with only a basin lymph node localization, with neither a cutaneous primary site nor distant metastases. From 1996 to 2020, among patients with histologically confirmed MCC managed at a neuroendocrine neoplasm-referral center, we selected those with an exclusive nodal basin, no distant metastasis, and an unknown primary site defined by cross-sectional and physical examination. A total of 55 out of 310 patients fulfilled the selection criteria. The median age was 64 years and the majority were males. Inguinal lymph-nodes were the most common anatomic site. With a median follow-up of 4.3 years, the 5-year relapse-free survival (RFS) rate was 56.6 (95% CI 42.0–68.8%) and the 5-year cancer specific survival (CSS) rate was 68.5 (95% CI 52.8–79.9%) for the whole population. The 36 patients (65.5%) undergoing lymphadenectomy (LND) + radiotherapy (RT) ± chemotherapy had a 5-year RFS rate of 87.2% (95% CI 65.5–95.7%) and a 5-year CSS rate of 90.5% (95% CI 67.0–97.5), which were better than those receiving LND alone. In a multivariable analysis, the survival benefit for LND + RT remained significant. Results from one of the largest single-center series of nMCC-UP suggest that a curative approach including RT can be effective, similar to what is observed for stage IIIB MCC. Multicentric studies with homogenous populations should be carried out in this controversial clinical entity, to minimize the risk of biases and provide robust data.
Open AccessNodal Merkel Cell Carcinoma with Unknown Primary Site and No Distant Metastasis: A Single-Center Series
Merkel cell carcinoma (MCC) is a very rare and aggressive neuroendocrine carcinoma originating from Merkel cells, typically with a skin nodule; however, it exceptionally presents with only a basin lymph node localization, with neither a cutaneous primary site nor distant metastases. From 1996 to 2020, among patients with histologically confirmed MCC managed at a neuroendocrine neoplasm-referral center, we selected those with an exclusive nodal basin, no distant metastasis, and an unknown primary site defined by cross-sectional and physical examination. A total of 55 out of 310 patients fulfilled the selection criteria. The median age was 64 years and the majority were males. Inguinal lymph-nodes were the most common anatomic site. With a median follow-up of 4.3 years, the 5-year relapse-free survival (RFS) rate was 56.6 (95% CI 42.0–68.8%) and the 5-year cancer specific survival (CSS) rate was 68.5 (95% CI 52.8–79.9%) for the whole population. The 36 patients (65.5%) undergoing lymphadenectomy (LND) + radiotherapy (RT) ± chemotherapy had a 5-year RFS rate of 87.2% (95% CI 65.5–95.7%) and a 5-year CSS rate of 90.5% (95% CI 67.0–97.5), which were better than those receiving LND alone. In a multivariable analysis, the survival benefit for LND + RT remained significant. Results from one of the largest single-center series of nMCC-UP suggest that a curative approach including RT can be effective, similar to what is observed for stage IIIB MCC. Multicentric studies with homogenous populations should be carried out in this controversial clinical entity, to minimize the risk of biases and provide robust data.
- 17 July 2021
- Published by Springer Nature
- p. 179-190
Gastric Neuroendocrine Tumors
- 1 May 2013
- Published by Elsevier in Digestive and Liver Disease
- Vol. 45 (5) , 396-402
Confocal laser endomicroscopy for in vivo diagnosis of Barrett's oesophagus and associated neoplasia: A pilot study conducted in a single Italian centre
- 1 May 2013
- Published by Elsevier in Digestive and Liver Disease
- Vol. 45 (5) , 396-402
Confocal laser endomicroscopy for in vivo diagnosis of Barrett's oesophagus and associated neoplasia: A pilot study conducted in a single Italian centre
- 1 April 2012
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 75 (4) , AB406
Mo1378 Endoscopic Submucosal Dissection(ESD)for Residual or Recurrent Colorectal Adenomas: a Single Center Experience
- 1 April 2012
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 75 (4) , AB406
Mo1378 Endoscopic Submucosal Dissection(ESD)for Residual or Recurrent Colorectal Adenomas: a Single Center Experience
- 10 May 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43 (8) , 636-641
Linear array ultrasonography to stage rectal neoplasias suitable for local treatment
- 10 May 2011
- Published by Elsevier in Digestive and Liver Disease
- Vol. 43 (8) , 636-641
Linear array ultrasonography to stage rectal neoplasias suitable for local treatment
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
715 Detection of Anal Intraepithelial Neoplasia and Anal Carcinoma In-Vivo Using Confocal Laser Endomicroscopy
- 31 May 2010
- Published by Elsevier in Gastroenterology
- Vol. 138 (5)
715 Detection of Anal Intraepithelial Neoplasia and Anal Carcinoma In-Vivo Using Confocal Laser Endomicroscopy
- 31 March 2010
- Published by Elsevier in Digestive and Liver Disease
- Vol. 42 (3) , 185-190
Positron emission tomography for the detection of colorectal adenomas
- 31 March 2010
- Published by Elsevier in Digestive and Liver Disease
- Vol. 42 (3) , 185-190
Positron emission tomography for the detection of colorectal adenomas